Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helge Taubert

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
Scientific Reports|March 26, 2025
The MicroRNA miR-454 and the mediator complex component MED12 are regulators of the androgen receptor pathway in prostate cancerJuan Guzman, Martin Hart, Katrin Weigelt, et al.
Clinical and Translational Radiation Oncology|March 30, 2018
P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patientsMatthias Kappler, Johanna Kotrba, Tom Kaune, et al.
International Journal of Molecular Sciences|January 8, 2025
Functional and Biological Characterization of the LGR5Δ5 Splice Variant in HEK293T CellsMatthias Kappler, Laura Thielemann, Markus Glaß, et al.
Cancer Management and Research|August 27, 2021
The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder CancerDanijel Sikic, Helge Taubert, Johannes Breyer, et al.
Scientific Reports|June 11, 2026
Expression of progranulin (GP88) protein appears as an independent prognostic factor for clinical progression in high-risk prostate cancer patientsRenata Dubrovska, Markus Eckstein, Rudolf Jung, et al.
BMC Cancer|February 17, 2019
Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patientsSwetlana Rot, Tom Kaune, Helge Taubert, et al.
Biomed Research International|May 31, 2014
Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancerOmar Al-Janabi, Helge Taubert, Andrea Lohse-Fischer, et al.
Cancers|June 2, 2021
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer PatientsVeronika Weyerer, Pamela L Strissel, Reiner Strick, et al.
Oncotarget|March 15, 2018
Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patientsVerena Lieb, Katrin Weigelt, Lena Scheinost, et al.
Cell|November 20, 2004
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humansGareth L Bond, Wenwei Hu, Elisabeth E Bond, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Scientific Reports|March 26, 2025
The MicroRNA miR-454 and the mediator complex component MED12 are regulators of the androgen receptor pathway in prostate cancerJuan Guzman, Martin Hart, Katrin Weigelt, et al.
Clinical and Translational Radiation Oncology|March 30, 2018
P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patientsMatthias Kappler, Johanna Kotrba, Tom Kaune, et al.
International Journal of Molecular Sciences|January 8, 2025
Functional and Biological Characterization of the LGR5Δ5 Splice Variant in HEK293T CellsMatthias Kappler, Laura Thielemann, Markus Glaß, et al.
Cancer Management and Research|August 27, 2021
The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder CancerDanijel Sikic, Helge Taubert, Johannes Breyer, et al.
Scientific Reports|June 11, 2026
Expression of progranulin (GP88) protein appears as an independent prognostic factor for clinical progression in high-risk prostate cancer patientsRenata Dubrovska, Markus Eckstein, Rudolf Jung, et al.
BMC Cancer|February 17, 2019
Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patientsSwetlana Rot, Tom Kaune, Helge Taubert, et al.
Biomed Research International|May 31, 2014
Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancerOmar Al-Janabi, Helge Taubert, Andrea Lohse-Fischer, et al.
Cancers|June 2, 2021
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer PatientsVeronika Weyerer, Pamela L Strissel, Reiner Strick, et al.
Oncotarget|March 15, 2018
Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patientsVerena Lieb, Katrin Weigelt, Lena Scheinost, et al.
Cell|November 20, 2004
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humansGareth L Bond, Wenwei Hu, Elisabeth E Bond, et al.
Pageof 17